These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort. Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173 [TBL] [Abstract][Full Text] [Related]
11. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Yu L; Baxter PA; Voicu H; Gurusiddappa S; Zhao Y; Adesina A; Man TK; Shu Q; Zhang YJ; Zhao XM; Su JM; Perlaky L; Dauser R; Chintagumpala M; Lau CC; Blaney SM; Rao PH; Leung HC; Li XN Neuro Oncol; 2010 Jun; 12(6):580-94. PubMed ID: 20511191 [TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups. Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133 [TBL] [Abstract][Full Text] [Related]
13. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548 [TBL] [Abstract][Full Text] [Related]
14. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. Merchant TE; Bendel AE; Sabin ND; Burger PC; Shaw DW; Chang E; Wu S; Zhou T; Eisenstat DD; Foreman NK; Fuller CE; Anderson ET; Hukin J; Lau CC; Pollack IF; Laningham FH; Lustig RH; Armstrong FD; Handler MH; Williams-Hughes C; Kessel S; Kocak M; Ellison DW; Ramaswamy V J Clin Oncol; 2019 Apr; 37(12):974-983. PubMed ID: 30811284 [TBL] [Abstract][Full Text] [Related]
15. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors. Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520 [TBL] [Abstract][Full Text] [Related]
16. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015 [TBL] [Abstract][Full Text] [Related]
17. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma. Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357 [TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803 [TBL] [Abstract][Full Text] [Related]
19. Development and characterization of human ependymoma xenograft HxBr5. Horowitz ME; Parham DM; Douglass EC; Kun LE; Houghton JA; Houghton PJ Cancer Res; 1987 Jan; 47(2):499-504. PubMed ID: 3791238 [TBL] [Abstract][Full Text] [Related]
20. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification. Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]